Synlogic (NASDAQ:SYBX) Receives “Buy” Rating from HC Wainwright

Synlogic (NASDAQ:SYBX)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a note issued to investors on Monday, AnalystRatings.com reports. They currently have a $13.00 price objective on the biotechnology company’s stock.

A number of other research analysts have also weighed in on the company. Oppenheimer restated a “hold” rating on shares of Synlogic in a report on Thursday, March 12th. Zacks Investment Research lowered Synlogic from a “strong-buy” rating to a “hold” rating in a report on Thursday, March 19th. Finally, ValuEngine upgraded Synlogic from a “hold” rating to a “buy” rating in a report on Friday, January 3rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $12.43.

SYBX stock traded down $0.09 during midday trading on Monday, reaching $1.96. The stock had a trading volume of 93,230 shares, compared to its average volume of 476,140. The company’s fifty day simple moving average is $2.18 and its 200 day simple moving average is $2.33. The company has a current ratio of 15.03, a quick ratio of 15.03 and a debt-to-equity ratio of 0.15. The company has a market cap of $64.82 million, a price-to-earnings ratio of -1.14 and a beta of 2.54. Synlogic has a 52-week low of $1.35 and a 52-week high of $10.01.

Synlogic (NASDAQ:SYBX) last announced its quarterly earnings data on Thursday, March 12th. The biotechnology company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.07. The company had revenue of $1.23 million for the quarter, compared to analyst estimates of $0.63 million. Synlogic had a negative return on equity of 33.22% and a negative net margin of 2,310.98%. Sell-side analysts predict that Synlogic will post -1.75 EPS for the current year.

Several institutional investors and hedge funds have recently modified their holdings of SYBX. Renaissance Technologies LLC increased its stake in shares of Synlogic by 96.0% in the 4th quarter. Renaissance Technologies LLC now owns 301,272 shares of the biotechnology company’s stock worth $777,000 after acquiring an additional 147,600 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Synlogic in the 4th quarter worth $262,000. Oxford Asset Management LLP acquired a new stake in shares of Synlogic in the 4th quarter worth $197,000. Bank of New York Mellon Corp increased its stake in shares of Synlogic by 150.3% in the 4th quarter. Bank of New York Mellon Corp now owns 126,232 shares of the biotechnology company’s stock worth $325,000 after acquiring an additional 75,793 shares during the last quarter. Finally, State Street Corp increased its stake in shares of Synlogic by 12.9% in the 3rd quarter. State Street Corp now owns 303,424 shares of the biotechnology company’s stock worth $695,000 after acquiring an additional 34,552 shares during the last quarter. 51.35% of the stock is owned by institutional investors and hedge funds.

About Synlogic

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

Further Reading: What is a Swap?

Analyst Recommendations for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.